Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Rosiglitazone for Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA: Participants must meet the following criteria for inclusion in the trial:~* Must sign and date the informed consent form~* At least 18 years of age~* Documented diagnosis (endoscopic, surgical or x-ray) of ulcerative colitis (UC)~* Mild to moderate ulcerative colitis indicated by Disease Activity Index score of greater than or equal to 4 and less than or equal to 10~* Unless the patient is intolerant of oral 5-ASA therapy, patient must be treated with a minimum of 2 gm daily of an oral 5-ASA agent for a minimum of 4 weeks during the current exacerbation of ulcerative colitis or immediately prior to study entry~* If treated with oral corticosteroids, dose must not exceed 20 mg per day of Prednisone or equivalent~* If treated with corticosteroids, dose must be stable for 4 weeks prior to study entry and remain on same dose throughout~* If treated with 6-mercaptopurine or azathioprine, must have been on medication for 4 months and a stable dose for 2 months prior to study entry~* If a female of childbearing age, the participant must have a negative serum pregnancy test and have been using a medically approved form of contraceptive birth control for 3 months prior to enrollment. Participants, both male and female, must also be willing to use medically approved contraceptive birth control (at least one barrier method) throughout the study~* If treated with rectal therapy, dose must be stable for 2 weeks prior to study entry and remain on same dose throughout~EXCLUSION CRITERIA: Participants will be ineligible for participation in the trial if they meet any of the following criteria:~* Severe ulcerative colitis indicated by Disease Activity Index score of greater than 10~* Class III or IV congestive heart failure by NYHA classification system~* Allergy to thiazolidinediones~* Presence of any medical condition with an expected survival of less than 1 year~* Participants receiving therapy with cyclosporin, anti-TNF therapy, or methotrexate within the last 2 months of screening~* Positive stool culture for enteric pathogens (salmonella, shigella, and campylobacter), positive C.difficile toxin, or positive stool ova and parasite exam~* Positive proteinuria by urine dipstick~* History of chronic liver disease or baseline liver chemistries greater than the upper limit of normal~* Diabetes mellitus requiring hypoglycemic agents~* Participation in study of experimental therapy within 2 months of first screening visit~* Has any of the following laboratory abnormalities: WBC \< 3,000 per uL, Neutrophil \< 1,000 cell/cu.mm, Platelets \<75,000 per uL, INR \> 1.2~* Participant is female and is pregnant or currently breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Rosiglitazone (Type: EXPERIMENTAL): 4 mg of rosiglitazone taken twice daily for 12 weeks.
- placebo (Type: PLACEBO_COMPARATOR): Identical in appearance to study drug taken twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).